Myopia

New research reveals collagen mimetic peptides may effectively restore ocular tissue stiffness, offering hope for myopia and other eye diseases.

A recent study reveals that ADHD in schoolchildren correlates with lower myopia prevalence and shorter eye length, suggesting intriguing links between vision and attention disorders.

The primary study outcomes were the cumulative incidence rate of myopia, with myopia defined as an SER −0.50 diopter (D) or less and the percentage of participants who had a fast myopic shift that was defined as a spherical equivalent myopic shift of 0.50 D or greater over the course of 1 year.

A study reveals that secondhand smoke significantly increases the risk of myopia in Chinese children, highlighting the need for smoke-free environments.

Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.

Optometrists learn to recognize and manage pediatric dry eye and myopia, emphasizing proactive care and lifestyle changes for better outcomes.

The expansion includes community health centers in the greater Boston area and Rhode Island.

Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.

The 0.1 mg/mL atropine eye drop for pediatric myopia is licensed from Sydnexis, Inc.

An official approval by the FDA in the United States can boost adoption rate of atropine and antimyopia glasses, which will change the landscape of myopia management.

IVMED-85 is a preservative-free, nonatropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

Increases in the doses of atropine were most common following the pandemic and especially among patients for whom therapy was initiated with the 0.01% dose.

New data from North American and Chinese clinical trials reinforce the safety, efficacy, and durability of DOT lenses in slowing pediatric myopia progression, without evidence of rebound.

At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

The CATHAY trial evaluated 186 myopic children, 6 to 13 years old at initiation, across 5 hospitals.

Eva Kim, MD, offers valuable insights into why EVO ICL is becoming a compelling alternative to traditional corneal procedures like LASIK.

In honor of the Myopia Management Navigator’s 1-year anniversary, Dr Tucker shares clinical insights, practical tips, and business opportunities for optometrists looking to expand their scope and elevate patient care through evidence-based myopia management.

Researchers found that repeated therapy using low-level red light (RLRL) is a potential intervention to control myopia progression in children.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

How studies into myopia management can increase access to vision care.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary end point for slowing pediatric myopia progression.